Pegfilgrastim Versus Filgrastim - Intraindividual Comparison of Quantity and Quality of Mobilized Peripheral Blood Stem Cells in Patients With Non Hodgkin-lymphoma

Trial Profile

Pegfilgrastim Versus Filgrastim - Intraindividual Comparison of Quantity and Quality of Mobilized Peripheral Blood Stem Cells in Patients With Non Hodgkin-lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2014

At a glance

  • Drugs Pegfilgrastim (Primary) ; Cisplatin; Epirubicin; Etoposide; Filgrastim; Ifosfamide; Rituximab
  • Indications Non-Hodgkin's lymphoma; Stem cell mobilisation
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top